Unicycive Therapeutics (NASDAQ:UNCY) had its "buy" rating reaffirmed by analysts at Guggenheim.
Unicycive resubmits NDA for hyperphosphatemia asset [Seeking Alpha]
Companies Like Unicycive Therapeutics (NASDAQ:UNCY) Are In A Position To Invest In Growth [Yahoo! Finance]
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) [Yahoo! Finance]
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)